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  ملخصال
بكتيريا االشيريشيا كوالي إلفراز إنـزيم تهدف هذه الدراسة إلى كشف مدى إمكانية 
 ميكروباً من )300(ولقد تم تحديد نسبة إفراز هذا اإلنزيم بين . بيتاالكتاميز الواسع المدى 
 من العدد الكلي يفرز هذا )%(3.7ميكروباً ) 11 (ولقد بينت النتائج أن. االشيريشيا كوالي
مقاومة عالية  لألموكسيسلين  نزيموأظهرت معظم الميكروبات التي تفرز هذا اإل. اإلنزيم
 )%100.0(والسيفالكسين والسفيروكسيم والسيفوتكسيم حيث وصلت نسبة مقاومتهم إلـى 
ومن الواضح بعد تحليل البيانات أن كل الميكروبات المفـرزة . )%81.8(والجنتاميسين 
كمـا أن . رإلنزيم بيتاالكتاميز الواسع المدى كانت مقاومة ألربعة مضادات حيوية أو أكث 
وقـد تبـين بالتحليـل .  كانت مقاومة لتسعة من المضادات الحيويـة )%(36.4الغالبية 
اإلحصائي وجود عالقة معنوية قوية بين الميكروبات التي تفرز هذا اإلنزيم وبين كٍل من 
االستخدام السابق للمضادات الحيوية ودخول المستشفى وااللتهابـات الـسابقة للمـسالك 
  .البولية
Abstract 
This study was designed in order to detect the production of extended 
spectrum beta-lactamase (ESBL) in the isolated Escherichia coli. The 
prevalence of ESBL production was determined among 300 isolates of E. coli. 
Eleven (3.7%) isolates proved to be ESBL. High resistance especially, to 
amoxycillin, cephalexin, cefuroxime, cefotaxime (100.0%) and gentamicin 
(81.8%) was observed. It was also observed that, all ESBL-producers displayed 
multiple resistance to four or more antimicrobial agents and the majority of the 
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isolates (36.4%) were resistant to nine agents. Moreover, a highly significant 
association has been found between infection with ESBL-producers and the 
patients’ prior antimicrobials use, previous hospitalization and preceding UTI. 
Introduction: 
Extended-spectrum beta-lactamases (ESBLs) are enzymes that 
mediate resistance to extended-spectrum cephalosporins and monobactams. 
These enzymes are produced mainly by Klebsiella pneumoniae and 
Escherichia coli (Yates, 1999 and Luzzaro et al., 2001). Although, they 
have been detected in other organisms including Salmonella species, 
Pseudomonas aeruginosa and other enterobacteriaceae (Kaye et al., 2000).  
The first bacterial isolate resistant to the so-called extended-spectrum 
cephalosporins was identified in Germany in 1983 (Stobberingh et al., 1999). 
And soon after, in several European countries such as France, Italy, Greece and 
Austria. ESBLs have also been detected in the USA and in Western Australia 
(Stobberingh et al., 1999). Subsequently, much of the dramatic increase in 
bacterial resistance to beta-lactam antibiotics has been associated with the 
spread of ESBLs worldwide (Canadian External Quality Assessment, 1998). 
It is known that ESBL producing strains can survive in the hospital 
environment (Hobson et al., 1996). Outbreaks due to the dissemination of 
various ESBL-producing enterobacteriaceae species in hospitals and other 
health care facilities has been reported (Cormican et al., 1996).  
Boundaries between community and hospital environments are, 
however, becoming more blurred and this trend will continue due to the 
shift towards shorter hospital stays, the provision of more treatment at home 
(even of patients with severe and complicated illnesses) and the use of more 
short stay surgical interventions. This may have consequences for the 
development of resistance to antimicrobial drugs and spread of resistant 
strains in the community (Goossens & Sprenger, 1998). 
Overcrowding, the increasing number of immunocompromized 
patients, increased travelling, the widespread use of broad-spectrum 
antibiotics, the sale of antibiotics over the counter and the inappropriate use 
of antibiotics are other contributing factors to the emergence of bacterial 
resistance in the community. 
The aim of this study was to detect the production of ESBL in E. coli 
isolated from the community in the Gaza Strip, evaluate the susceptibility of 
ESBL-producers to various antimicrobial agents and to investigate some of 
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Materials and Methods: 
Data were collected via patient interviews, or the patient's family and 
analysis of 300 E. coli isolated from outpatient females with clinical 
evidence of community-acquired urinary tract infections (UTI) during the 
year 2001 in the Gaza Strip. Identification of organisms was based on 
colonial morphology, Gram stain reaction and biochemical characteristics 
(Burnett et al., 1994 and Vandepitte et al., 1996). For confirmation of E. coli 
strains, a commercial identification biochemical system (API 20 E 
bioMerieux) was used (Baron et al., 1994). 
E. coli isolates were then stored in Mueller Hinton broth supplemented with 
15% glycerol at –85 °C until further analysis. 
The susceptibility of the 300 isolates to twelve antimicrobial agents was 
determined by the Kirby-Bauer disk diffusion technique on Mueller Hinton 
agar plates according to the NCCLS recommendations (NCCLS, 2001).  
 The disks and concentrations of the twelve antimicrobial agents that 
are commonly used for the treatment of UTIs in our region were as follows: 
amoxycillin (25 µg), amoxycillin-clavulanic acid (30 µg), cephalexin (30 
µg), cefuroxime (30 µg), cefotaxime (30 µg), cotrimoxazole (1.25-23.75 µg), 
nalidixic acid (30 µg), ciprofloxacin (5 µg), tetracycline (30 UI), amikacin 
(30 µg), gentamicin (30 µg) and nitrofurantoin (300 µg). 
Resistance to cefpodoxime disk (10 µg) has been studied as a 
screening method for ESBL production by disk diffusion technique, using 
sensitivity break point of < 21 mm (Kaye et al., 2000).  
The Epsilometer test (E-test) method was used for confirmation of 
ESBL production (AB Biodisk, Solna, Sweden). The strips were used 
according to the manufacturer’s instructions. Briefly, an overnight culture of 
the microorganism diluted to a turbidity equal to that of 0.5 McFarland units 
was swabbed on Mueller Hinton agar plates. After drying for 15 min, the E-
test strips were applied on the plates and incubated at 37°C for 18 to 24 
hours. The MICs on both ends were read on the intersection of the inhibition 
ellipse and the E-strip edge. A ratio of MIC ceftazidime, ceftazidime-
clavulanic acid and MIC cefotaxime, cefotaxime-clavulanic acid equal to 8 
or greater was considered to be ESBL-positive (Stobberingh et al., 1999). 
The E-test was also used for determining the MIC values of the 
antimicrobial agents used in this study. 
The quality of performance was controlled once weekly, using the 
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coli ATCC 35 218 to control results of disks that contain combination of 
beta-lactam antibiotics and a beta-lactamase inhibitor. 
The Chi-square test was used for the statistical analysis of the data 
and P-values of < 0.05 were considered significant. 
Results: 
The data analysis of the 300 E. coli isolates revealed that, a total of 
48 (16.0%) of the isolates were sensitive to all the antimicrobial agents 
tested. The remaining 252 (84.0%) of the isolates showed different 
resistance patterns. 
Putative ESBL-production was observed in 11 (3.7%) of the 300 E. 
coli isolates. All putative ESBL-producers were found to be resistant to 
cefpodoxime according to the disk diffusion test. 
 By calculating the ratio of MIC ceftazidime, ceftazidime-clavulanic acid 
and cefotaxime, cefotaxime-clavulanic acid, the results confirmed that the 
11 isolates have ratios greater than 8 and were thus considered ESBL-
producers (Table 1).   
Table (2) represents the percentage of resistance of ESBL-producers to the 
twelve antimicrobials tested. Most of the isolates showed high resistance 
especially, to amoxycillin (100.0%), cephalosporins (100.0%) and 
gentamicin (81.8%). All the isolates, however, were completely sensitive to 
amoxycillin-clavulanic acid and nitrofurantoin. 
Resistance of ESBL-positive isolates have been confirmed by the E-
test. Table (3) demonstrates the distribution of the MICs resistance ranges 
for the different agents.  
The MICs of amoxycillin as well as of cotrimoxazole and 
tetracycline were high and all reached the resistance breakpoints of 256, 32 
and 256 µg/ml, respectively. 
The MICs of nalidixic acid were clustered around the breakpoint of 
256 µg/ml with a mean of 237.7µg/ml. 
On the other hand, gentamicin resistant ESBL-producers showed MICs that 
ranged from 8 to 256 µg/ml with a mean of 38.2 µg/ml.  
The MICs of cephalexin and cefuroxime were in the range of 32-256 µg/ml 
with a mean of 197.8 and 189.1µg/ml, respectively.  
It is evident from the data that, all ESBL-producers were resistant to 
four or more antimicrobial agents and that the majority of the isolates 
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The 11 ESBL-producing isolates were analyzed with respect to the 
patients’ prior antimicrobials use, previous hospitalization and preceding UTI. 
Table (4), shows that, all the ESBL-producers were isolated from patients 
who had used antimicrobials. In addition, 10 (90.9%) of the isolates were 
collected from patients with previous hospitalization. Whereas, 9 (81.8%) of 
the ESBL producers were isolated from those with previous UTI.  
Chi-square analysis indicated that the association between the ESBL-producers 
and all the studied patients’ characteristics is highly significant (P<0.001). 
Discussion: 
The results of this study confirmed that, out of 300 E. coli isolates, 
11(3.7%) of the isolates were ESBL-producers. Lower ratios have been 
reported by many investigators, worldwide. For instance, Stobberingh et al. 
(1999) and De Champs et al.(2000) noted that, ESBL-producing E.coli 
ranged from 0.1 to 1.5%.However, other investigators have reported higher 
ratios. For example, in Greece, Vatopoulos et al.(1990),in Korea, Pai et al. 
(1999),in New York, Saurina et al.(2000) and in some USA hospitals Kaye et 
al.(2000) indicated that, ESBL-producing isolates ranged from 4.0 to 40.0%. 
 Similarities and differences in data concerning antimicrobial 
resistance may be due to the fact that they may have been collected on 
different periods. Also, the investigated target populations may have various 
sociodemographical, socioeconomical, socioepidemiological and clinical 
parameters.  
Table (2) represents resistance rate of ESBL-producers to twelve 
antimicrobials. Most of the isolates showed co-resistance to non beta-lactam 
antimicrobials, especially to cotrimoxazole, gentamicin, nalidixic acid and 
ciprofloxacin. They, however, were completely sensitive to amoxycillin-
clavulanic acid and nitrofurantoin. In this regard, we can conclude that, for 
E. coli isolates, amoxycillin-clavulanic acid, nitrofurantoin and amikacin 
remain effective treatment options.  
 This study showed that, all ESBL-producing isolates were resistant 
to four or more antimicrobial agents and the majority of them (36.4%) were 
resistant to nine agents. 
The considerably high MIC values of amoxycillin, cotrimoxazole, 
tetracycline, nalidixic acid, cephalexin and cefuroxime (Table-3) reflect the 
extent of treatment problem for ESBL-producing isolates. 
Jett et al. (1995), observed that, 65% of ESBL-producing isolates 
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ciprofloxacin or gentamicin). In another finding by Livermore & Yuan 
(1996), an association between ESBL production and aminoglycosides 
resistance has been reported where, four out of six ESBL-positive strains 
were resistant to most aminoglycosides. 
 Table (4) summarizes the relation between the ESBL-positive 
isolates and patients’ prior antimicrobials use, previous hospitalization and 
preceding UTI. A highly statistical significance was found between the 
ESBL-producers and all studied patients’ characteristics (P<0.001). 
Similar finding was reported by Kim et al. (2002) who have shown 
that, the risk factors for infection with ESBL-producing organisms were 
prior hospitalization, prior use of oxyimino-cephalosporins and admission to 
an intensive care units.     
 This study clearly shows that, infection with these highly resistant 
isolates, which is usually confined to hospitals, is now being acquired in the 
community. Thus, we recommend continuos surveillance for ESBL-
producing isolates in both hospitals and community in order to develop 
programs for controlling the spread of these isolates which will increase the 
problem of community acquired UTIs treatment. 
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Table (1): The MICs ratio of the ESBL-producing isolates. 
MIC ratio for ESBL confirmation agents 




168.4 0.19 > 32  340.4 0.047  > 16  93 
64.0 0.5  > 32  64.0 0.25  > 16  111 
31.9 0. 094  3.0  500.0 0.032  > 16  113 
64.0 0.5  > 32  64.0 0.25  16  117 
128 0. 125 16.0  500.0 0.032  > 16  149 
10.6 0. 094  1.0  250.0 0.064  > 16  185 
15.9 0. 094  1.5  500.0 0.032  > 16 242 
10.5 0.19  2.0  84.2 0.19  > 16  280 
84.2 0.38 > 32  42.1 0.38  > 16  281 
168.4 0.19  > 32  340.4 0.047  > 16  285 
16.0 0.5  8.0  64.0 0.25  > 16  288 
CT, cefotaxime; CTL, cefotaxime-clavulanic acid; TZ, ceftazidime; TZL, ceftazidime-
clavulanic acid; CT/CTL; cefotaxime to cefotaxime-clavulanic acid ratio; TZ/TZL, ceftazidime 
to ceftazidime-clavulanic acid ratio. 







AMX 0.0 (0) 100.0 (11) 
CF  0.0 (0) 100.0 (11) 
CMX 0.0 (0) 100.0 (11) 
CXT 0.0 (0) 100.0 (11) 
SXT 18.2 (2) 81.8 (9) 
GM 18.2 (2) 81.8 (9) 
NA 36.4 (4) 63.6 (7) 
CIP  45.5 (5) 54.5 (6) 
TE  54.5 (6) 45.5 (5) 
AN  90.9 (10) 9.1 (1) 
ACM 100.0 (11) 0.0 (0) 
NTFN 100.0 (11) 0.0 (0) 
*No.=number of isolates 
AMX, Amoxycillin; SXT, Cotrimoxazole; TE, Tetracycline; NA, Nalidixic acid; 
CIP, Ciprofloxacin; GM, Gentamicin; CF, Cephalexin; CMX, Cefuroxime; CXT, 
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Table (3): The MIC values for drug resistant ESBL-producing isolates  
 
























































93 256 32 256 256 32 8 256 256 32 S S S 
111  256 32  S  256 4 48 48 32 16 S S S 
113  256 32 256 128  S 64 256 256 32 S S 48 
117 256 32 S 256 4 48 48 32 16 S S S 
149 256 32 256 256 32 16 256 256 32 S S S 
185  256 32 256 256 32 S 64 256 24 S S S 
242 256 32 S S S 64 128 256 32 S S S 
280 256 S S S S 16 256 256 32 S S S 
281 256 32 256 256 32 32 256 256 32 S S S 
285  256 S S S S S 256 64 32 S S S 
288 256 32 S S S 48 256 256 32 S S S 
Mean MIC 
(µg/ml) 
256 32 256 237.7 22.6 38.2 189.1 197.8 28.4 S S 48 
S=Sensitive (less than the lower value for each of the resistant ranges) 
 
Table (4): The relation between ESBL-producers and patients’ characteristics 
among resistant isolates. 
 
Non ESBL-producer % (n) ESBL-producer % (n)*Variable 
    Prior antimicrobial use** 
83.8 (202)  100.0 (11)  Yes  
16.2 (39)  0.0 (0)  No  
100.0 (241)  100.0 (11)  Total 
    Previous hospitalization** 
41.1 (99)  90.9 (10)  Yes  
58.9 (142)  9.1 (1)  No  
100.0 (241)  100.0 (11)  Total 
    Preceding UTI** 
32.4 (78)  81.8 (9)  Yes  
67.6 (163) 18.2 (2)  No  
100.0 (241)  100.0 (11)  Total 
*(n)=number of isolates  
**=Significant at P-value of <0.05 
